Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective comprehensive profiling of immune responses to COVID-19 vaccination in patients on zanubrutinib therapy.
Nguyen THO, Lim C, Lasica M, Whitechurch A, Tennakoon S, Saunders NR, Allen LF, Rowntree LC, Chua BY, Kedzierski L, Tan HX, Wheatley AK, Kent SJ, Karapanagiotidis T, Nicholson S, Williamson DA, Slavin MA, Tam CS, Kedzierska K, Teh BW. Nguyen THO, et al. Among authors: lasica m. EJHaem. 2023 Jan 20;4(1):216-220. doi: 10.1002/jha2.639. eCollection 2023 Feb. EJHaem. 2023. PMID: 36819189 Free PMC article.
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.
Tam CS, Gregory GP, Ku M, Fleming S, Handunnetti SM, Lee D, Walker P, Perkins A, Lew TE, Sirdesai S, Chua CC, Gilbertson M, Lasica M, Anderson MA, Renwick W, Grigg A, Patil S, Opat S, Friebe A, Cooke R, De Boer J, Spencer A, Ritchie D, Agarwal R, Blombery P. Tam CS, et al. Among authors: lasica m. Intern Med J. 2022 Jul;52(7):1286-1287. doi: 10.1111/imj.15851. Intern Med J. 2022. PMID: 35879233 No abstract available.
[No title available]
[No authors listed] [No authors listed] PMID: 36163871
Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells.
Nguyen THO, Rowntree LC, Allen LF, Chua BY, Kedzierski L, Lim C, Lasica M, Tennakoon GS, Saunders NR, Crane M, Chee L, Seymour JF, Anderson MA, Whitechurch A, Clemens EB, Zhang W, Chang SY, Habel JR, Jia X, McQuilten HA, Minervina AA, Pogorelyy MV, Chaurasia P, Petersen J, Menon T, Hensen L, Neil JA, Mordant FL, Tan HX, Cabug AF, Wheatley AK, Kent SJ, Subbarao K, Karapanagiotidis T, Huang H, Vo LK, Cain NL, Nicholson S, Krammer F, Gibney G, James F, Trevillyan JM, Trubiano JA, Mitchell J, Christensen B, Bond KA, Williamson DA, Rossjohn J, Crawford JC, Thomas PG, Thursky KA, Slavin MA, Tam CS, Teh BW, Kedzierska K. Nguyen THO, et al. Among authors: lasica m. Cell Rep Med. 2023 Apr 18;4(4):101017. doi: 10.1016/j.xcrm.2023.101017. Epub 2023 Mar 27. Cell Rep Med. 2023. PMID: 37030296 Free PMC article.
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia.
Lasica M, Willcox A, Burbury K, Ross DM, Branford S, Butler J, Filshie R, Januszewicz H, Joske D, Mills A, Simpson D, Tam C, Taylor K, Watson AM, Wolf M, Grigg A. Lasica M, et al. Leuk Lymphoma. 2019 Jul;60(7):1796-1802. doi: 10.1080/10428194.2018.1551533. Epub 2019 Jan 11. Leuk Lymphoma. 2019. PMID: 30632843
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.
Ailawadhi S, Chen Z, Huang B, Paulus A, Collins MC, Fu LT, Li M, Ahmad M, Men L, Wang H, Davids MS, Liang E, Mekala DJ, He Z, Lasica M, Yannakou CK, Parrondo R, Glass L, Yang D, Chanan-Khan A, Zhai Y. Ailawadhi S, et al. Among authors: lasica m. Clin Cancer Res. 2023 Jul 5;29(13):2385-2393. doi: 10.1158/1078-0432.CCR-22-3321. Clin Cancer Res. 2023. PMID: 37074726 Free PMC article.
19 results